Microneedle-based transdermal delivery of therapeutics for rheumatoid arthritis

The article provides a concise overview of the significance of microneedles and loaded technologies including traditional pharmaceuticals, small molecule drugs and nanotechnology in the field of regenerative medicine. Rheumatoid Arthritis (RA) is a chronic inflammatory condition leading to the destruction of joints, decreased functioning, and added mortality. Conventional therapies such as NSAIDs, glucocorticoids, and DMARDS are poorly targeted, exhibit systemic side effects, and require large dosages. Microneedle technology is a painless and efficient method for applying drugs through the skin in a patient-friendly manner. Various classification methods have been used earlier to describe the different types of MNs; commonly, they are divided into five classes: solid, coated, dissolving, hollow, and hydrogel-forming types with varying drug release patterns. On the other hand, integration of nanotech-based compounds with MNs has greatly improved their capability of delivering small molecules and biologics to the inflamed joints. This targeted approach helps overcome the shortcomings of conventional therapies used in RA by providing controlled and localized release of drugs which can lead to improved therapeutic outcomes and reduced side effects compared to systemic treatments. Ongoing research and development are expected to accelerate clinical translation and broaden their involvement in next-generation RA treatments.